Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAXXIFY for dynamic forehead and glabellar lines
NCT06411002Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daxibotulinumtoxinA in glabellar lines, sponsored by Revance Therapeutics. Started Apr 2024; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06411002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411002.